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BLETTER TO THE EDITOR
e: Imatinib Mesylate Administration in the First 100
ays after Stem Cell Transplantation
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wRelapse remains a major cause of treatment failure
fter allogeneic stem cell transplantation (allo-SCT)
or Philadelphia chromosome–positive (Ph) chronic
yeloid leukemia (CML) beyond the ﬁrst chronic
hase and Ph acute lymphoblastic leukemia (ALL).
he 2-year relapse rate is 35%, 42%, and 55% for
h CML patients who receive transplants from
LA-identical siblings in second chronic phase, ac-
elerated phase, and blastic phase, respectively [1].
he 2-year probability of relapse is 32% to 57% after
llo-SCT in patients with Ph ALL [2] .
The management of relapse in these cases remains
ontroversial [3]. Salvage chemotherapy, -interferon,
onor leukocyte infusions, and, in selected cases, a
econd allo-SCT have been used. More recently, ima-
inib has gained a prominent role as salvage therapy
or documented recurrences of Ph CML after allo-
CT [4]. An alternative approach would in principle
e a prophylactic one. Imatinib could be administered
o high-risk patients on an adjuvant basis to prevent
isease recurrence. Approximately half (51%) of all
elapses after allo-SCT for CML occur during the
rst year after transplantation [3]. Therefore, if the
hance of relapse in high-risk patients is to be mini-
ized, it would seem advisable to start imatinib early
ie, in the ﬁrst 100 days after SCT), when the leukemic
ell load is presumably at its lowest. We wish to report
ur preliminary anecdotal experience in this area.
Over 12 months, 15 patients (median age, 42 years;
ange, 16-69 years) received imatinib in the ﬁrst 100
ays after SCT (allo-SCT, n  14; autologous SCT,
 1). These patients represented 52% of the total
umber of Ph CML and Ph acute leukemia pa-
ients allografted or autografted at our center during
he same time period (n  29). The review was ap-
roved by our institutional review board. Patients re-
eived imatinib entirely at the discretion of their at-
ending physician. No speciﬁc selection criteria and
o consistent dose-escalation scheme were followed.
iagnoses included PhCML (n 8), Ph ALL (n
), and Ph acute myeloid leukemia (n  1). All
atients received a fully ablative preparative regimen
nd achieved full donor-derived engraftment. Tacroli-
us and low-dose methotrexate were administered as p
B&MTraft-versus-host disease prophylaxis. The median day
f imatinib initiation after transplantation was day
34 (range, 16-37). All patients were still receiving
mmunosuppressive therapy (ie, tacrolimus) and had
o cytogenetic or molecular evidence of disease.
Initial imatinib doses ranged from 100 to 400 mg/d.
he average daily dose administered was 100 mg.
oses exceeding 200 mg/d were associated with sig-
iﬁcant (albeit transient and fully reversible) myelo-
uppression, which required both imatinib dose re-
uction and initiation of transfusion and growth factor
upport to achieve graft recovery. At all doses, ima-
inib was associated with fully reversible hematologic
oxicity; grade 3 and 4 neutropenia was observed in
0% and 27% of patients, respectively (National Can-
er Institute common toxicity criteria) [5]. Signiﬁcant
hrombocytopenia was also noted; grade 3 and 4 tox-
city was observed in 27% and 20% of all patients
valuated, respectively. Nonhematologic toxicities
ere uncommon. Periorbital edema/weight gain and
ransient increases in total bilirubin (1.0 to 2.3 mg/dL)
ere noted in 1 patient each (7%). Two patients
13%) relapsed while receiving imatinib during the
rst 100 days (Ph acute myeloid leukemia, n  1;
ML in blastic phase, n  1).
The administration of imatinib was found to predict-
bly increase tacrolimus serum levels by 25% to 33%
ithin 72 hours of medication initiation. Subsequent
mpiric tacrolimus dose reduction of 25% at the time of
matinib initiation prevented further serum concentra-
ion ﬂuctuations. This observed interaction between
matinib and tacrolimus levels is likely related to a com-
etition between imatinib and tacrolimus for the hepatic
ytochrome P450 3A4/5 enzyme system [6].
These preliminary observations suggest that ima-
inib can be safely administered in the ﬁrst 100 days
fter SCT. Tolerated doses are usually lower than in
on-SCT patients, and close monitoring (particularly
ematologic) is required. Although a theoretical con-
ern in this setting is the possibility that such reduced
osages may favor the selection of spontaneously aris-
ng resistant clones, in view of the potential beneﬁts,
e believe that this “adjuvant” approach is worth ex-
loring, ideally in a randomized study.
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In the October issue of Biology of Blood and Marrow Transplantation (Vol. 11, No. 10, pp 728-733), the
abstracts from the Second Annual International Umbilical Cord Blood Symposium were prefaced by a
summary of the proceedings, which was written by Dr. John Wagner, Dr. Richard Champlin, and Dr.
Lawrence Petz. The authors’ names and their affiliations were omitted from the summary and should have
read as follows: John Wagner, MD, University of Minnesota, Richard Champlin, MD, M.D. Anderson Cancer
Center, Lawrence D. Petz, MD, StemCyte International Cord Blood Center. The production staff apologize for
this error.
